Table of Contents

company-logo

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Dividend Announcement

• Corcept Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Corcept Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Corcept Therapeutics Dividend History

Corcept Therapeutics Dividend Yield

Corcept Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Corcept Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Corcept Therapeutics Financial Ratios

P/E ratio43.19
PEG ratio-7.26
P/B ratio9.55
ROE24.68%
Payout ratio0.00%
Current ratio3.70
Quick ratio3.64
Cash Ratio1.09

Corcept Therapeutics Dividend FAQ

Does Corcept Therapeutics stock pay dividends?
Corcept Therapeutics does not currently pay dividends to its shareholders.
Has Corcept Therapeutics ever paid a dividend?
No, Corcept Therapeutics has no a history of paying dividends to its shareholders. Corcept Therapeutics is not known for its dividend payments.
Why doesn't Corcept Therapeutics pay dividends?
There are several potential reasons why Corcept Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Corcept Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Corcept Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Corcept Therapeutics a dividend aristocrat?
Corcept Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Corcept Therapeutics a dividend king?
Corcept Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Corcept Therapeutics a dividend stock?
No, Corcept Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Corcept Therapeutics stocks?
To buy Corcept Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Corcept Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.